Dr. LeBeau on the Potential Applicability of Shark Antibodies in Prostate Cancer
Aaron LeBeau, PhD, discusses the potential wide applicability of shark antibodies in developing imaging and therapeutic strategies in prostate cancer.
Dr. LeBeau on the Potential Utility of Shark VNAR Proteins in Prostate Cancer
Aaron LeBeau, PhD, discusses the potential of shark variable domain of new antigen receptor proteins in prostate cancer.
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
2 Clarke Drive Cranbury, NJ 08512